
- /
- Supported exchanges
- / US
- / LQDA.NASDAQ
Liquidia Technologies Inc (LQDA NASDAQ) stock market data APIs
Liquidia Technologies Inc Financial Data Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Liquidia Technologies Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Liquidia Technologies Inc data using free add-ons & libraries
Get Liquidia Technologies Inc Fundamental Data
Liquidia Technologies Inc Fundamental data includes:
- Net Revenue: 19 322 K
- EBITDA: -136 866 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.42
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Liquidia Technologies Inc News

SA Asks: Which biotechs could be acquired by year's end?
[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a signifi...


Noteworthy Thursday Option Activity: LQDA, WMB, BMY
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Liquidia Corp (Symbol: LQDA), where a total of 11,982 contracts have traded so far, represe...

Jefferies Highlights Yutrepia’s Market Edge in Supporting a Buy on Liquidia (LQDA)
Liquidia Corp. (NASDAQ:LQDA) is one of the most shorted stocks right now. On August 15, Jefferies analyst Amy Li initiated coverage on Liquidia Technologies Inc. (NASDAQ:LQDA) with a Buy rating and a ...

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
Shares of United Therapeutics UTHR surged 33% on Tuesday after it announced positive top-line results from the late-stage TETON-2 study evaluating the nebulized version of Tyvaso (treprostinil) in adu...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.